10
Loading video...

By Melissa Fleur Afshar
Reporter
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
A group of scientists could be getting closer to identifying the biological signals made when aging slows, potentially allowing researchers to test for longevity treatments without waiting years to see whether they extend life.
But independent experts stress that the findings, based mainly on male mice, do not mean a treatment to dramatically extend human life is around the corner.
“Can these findings be extrapolated to humans? Possibly, but not yet,” Justine Lewis, a nurse practitioner and owner of a longevity clinic, told Newsweek. “These findings are a promising step toward faster ways to test anti-aging treatments, but they come from mice, mostly males, and are a long way from a human therapy.”
Read More on Science
The study, published in Frontiers in Aging, examined how five interventions already known to extend lifespan in mice changed metabolites, small molecules involved in the body's chemical processes.
The goal was to determine whether very different longevity treatments leave behind common metabolic signals. If reliable signatures can be identified, scientists hope to eventually use them as early biomarkers of whether an intervention is likely to affect lifespan.
A Chemical Fingerprint of Longer Life
Researchers studied genetically diverse male UM-HET3 mice given one of four drugs, rapamycin, acarbose, 17α-estradiol or canagliflozin, beginning at 4 months old. Another group underwent caloric restriction, receiving 60 percent as much food as control mice.
The U.S. Interventions Testing Program has previously identified these drugs as extending lifespan in mice, while caloric restriction has been linked to longer, healthier lives in mice and other animals.
Eight months later, researchers analyzed metabolites in seven tissues: blood plasma, brain, liver, kidney, skeletal muscle, perigonadal fat and inguinal fat. Using a machine-learning method called XGBoost, they found that mice receiving the longevity interventions had metabolic fingerprints that differed from untreated animals before survival differences appeared.

...
To test whether the interventions created shared signals, researchers trained models using four treatments and asked them to recognize mice receiving the fifth, unseen treatment. The models succeeded in 33 of 35 comparisons across tissues and interventions.
“Five treatments took five different roads and left the same tire tracks,” Colleen Ann Murphy, a pathologist turned women’s healthspan physician, told Newsweek. “Nobody found a fountain of youth here. What they may have found is a fingerprint of longer life, and a way to spot it early.”
Several biological changes stood out. Ergothioneine, a dietary antioxidant found notably in mushrooms, increased in the brain and blood plasma under all five interventions, and in skeletal muscle under four. It was also the most influential metabolite for predicting longevity treatment in the brain.
All five interventions were also associated with increased long-chain polyunsaturated triacylglycerols containing DHA in the blood and decreases in shorter, more saturated fats and diacylglycerols. Cardiolipin, a mitochondrial fat that typically declines with age and heart failure, increased in skeletal muscle.
Lewis cautioned that ergothioneine's role remains unclear.
“We don’t know whether it’s contributing to longer lifespan or simply reflecting other changes happening in the body,” she said.
Could It Work in Humans?
When researchers applied the same machine-learning approach to female mice, predicted lifespan gains did not match the animals' actual survival benefits.
“That matters to me,” Murphy said. “Women live longer, age differently, and are still an afterthought in aging research.”
Researchers must also establish whether the metabolic patterns are specific to lifespan-extending interventions or could result from other long-term medications or dietary changes.
Some treatments studied are already used in humans. Acarbose and canagliflozin are diabetes drugs, while rapamycin has also attracted interest in longevity research. But Murphy warned against interpreting the mouse findings as a reason to self-medicate.
“A fingerprint isn’t a finish line,” she said. “Nobody should take a diabetes drug to age slower or buy ergothioneine gummies because of a mouse study.”
Lewis similarly said the immediate significance is more practical than revolutionary. The findings could make it easier to identify promising interventions for human research, she said.
“I don’t think this means we’re about to have a pill that helps people live to 120,” Lewis said. “But it does suggest we’re getting better at understanding what happens inside the body when aging slows, and that’s an important step toward developing treatments that could help people live longer, healthier lives.”
Newsweek reached out to the study's lead authors for more information.
Reference
Badenoch, B. et al. (2026). Multi-tissue metabolomic signatures of five longevity interventions converge on ergothioneine and lipid remodeling in male UM-HET3 mice. Frontiers in Aging. https://doi.org/10.3389/fragi.2026.1972744.
Newsweek’s reporters and editors used Martyn, our AI assistant, to produce this story. Learn more about Martyn here. Contact Newsweek editors on this story: Kara Dolman and Gray R. Thomas
View 0 Comments
Submit Correction
View Editorial & AI Guidelines